A Double-Masked, Randomized, Multicenter, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of SJP-0035 0.001% for the Treatment of Patients With Dry Eye Disease (DELTA-1 Study)
Phase of Trial: Phase III
Latest Information Update: 18 Apr 2019
Price : $35 *
At a glance
- Drugs Fonadelpar (Primary)
- Indications Dry eyes
- Focus Registrational; Therapeutic Use
- Acronyms DELTA-1 Study
- Sponsors Senju Pharmaceutical
- 13 Apr 2019 Status changed from active, no longer recruiting to completed.
- 15 Feb 2019 Planned End Date changed from 31 Jan 2019 to 31 Mar 2019.
- 15 Feb 2019 Planned primary completion date changed from 31 Jan 2019 to 31 Mar 2019.